Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Cellular drug resistance in childhood leukemia
A. J.P. Veerman
, G. J.L. Kaspers
,
R. Pieters
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
6
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Cellular drug resistance in childhood leukemia'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Childhood Leukemia
100%
Drug Resistance
100%
Prednisolone
75%
L-asparaginase
50%
Prognostic Factors
50%
In Vitro Resistance
50%
MTT Assay
50%
Drug Susceptibility Testing
50%
Clinical Trials
25%
Clinical Outcomes
25%
Patient Samples
25%
Monotherapy
25%
Pharmacokinetics
25%
Daunorubicin
25%
Malignant Cells
25%
Antileukemic Activity
25%
Response to Chemotherapy
25%
Multivariate Analysis
25%
Regression Analysis
25%
Clinical Response
25%
Cell Killing
25%
Immunophenotyping
25%
Prognostic Groups
25%
Immunophenotypic Profile
25%
Disease-free Survival
25%
Prognosis Prediction
25%
Group-based
25%
Drug Resistance Profiles
25%
Relapsed ALL
25%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Resistance
100%
Childhood Leukemia
100%
Prednisolone
42%
Asparaginase
28%
Clinical Trial
14%
Vincristine
14%
Chemotherapy
14%
Monotherapy
14%
Dexamethasone
14%
Clinical Study
14%
Daunorubicin
14%
Preclinical Study
14%
Disease Free Survival
14%
Pharmacokinetics
14%
Neuroscience
Drug Resistance
100%
In Vitro
42%
Prednisolone
42%
MTT Assay
28%
Asparaginase
28%
Vincristine
14%
Immunophenotyping
14%
Dexamethasone
14%
Leukocyte
14%
Daunorubicin
14%
Pharmacokinetics
14%
Biochemistry, Genetics and Molecular Biology
Drug Resistance
100%
Prednisolone
42%
Asparaginase
28%
MTT Assay
28%
Clinical Trial
14%
Clinical Study
14%
Leukocyte
14%
Pharmacokinetics
14%
Immunophenotyping
14%
Multivariate Analysis
14%
Disease Free Survival
14%
Daunorubicin
14%
Dexamethasone
14%